
PEC — Investor Relations & Filings
PharmaEssentia Corporation is a fully integrated global entity focused on the discovery, development, and commercialization of novel therapies for hematologic diseases and oncology. The company leverages a proprietary PEGylation technology platform to engineer long-acting protein therapeutics designed to improve patient outcomes. Its flagship product, BESREMi® (Ropeginterferon alfa-2b), represents a significant advancement in the treatment of Polycythemia Vera, having received regulatory approval from the US FDA and EU EMA as a first-line therapy. PharmaEssentia operates a comprehensive value chain, including internal R&D, clinical trial management, and cGMP-certified manufacturing facilities. By addressing unmet medical needs in rare blood disorders and various cancers, the company aims to deliver best-in-class treatments to global markets through its integrated research and production capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年5月22日內部人設質解質 | 2026-05-25 | Chinese | |
| 115年5月21日內部人設質解質 | 2026-05-22 | Chinese | |
| 公告更正本公司115年第一季合併財務報告附註 揭露內容 | 2026-05-19 | Chinese | |
| 115年05月法人說明會簡報 — 644620260514E001.pdf | 2026-05-14 | English | |
| 115年05月法人說明會簡報 — 644620260514M001.pdf | 2026-05-14 | English | |
| 115年05月法人說明會簡報 | 2026-05-14 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47004188 | 115年5月22日內部人設質解質 | 2026-05-25 | Chinese | ||
| 46781963 | 115年5月21日內部人設質解質 | 2026-05-22 | Chinese | ||
| 46534725 | 公告更正本公司115年第一季合併財務報告附註 揭露內容 | 2026-05-19 | Chinese | ||
| 46373910 | 115年05月法人說明會簡報 — 644620260514E001.pdf | 2026-05-14 | English | ||
| 46373909 | 115年05月法人說明會簡報 — 644620260514M001.pdf | 2026-05-14 | English | ||
| 46373908 | 115年05月法人說明會簡報 | 2026-05-14 | Chinese | ||
| 46368548 | 115年第1季財務報告書 — 202601_6446_AI1.pdf | 2026-05-14 | Chinese | ||
| 46362497 | 115年第1季海外子公司投資 | 2026-05-13 | Chinese | ||
| 46362007 | 115年第1季大陸投資 | 2026-05-13 | Chinese | ||
| 46366472 | 115年第1季權益變動表 | 2026-05-13 | Chinese | ||
| 46366283 | 115年第1季現金流量表 | 2026-05-13 | Chinese | ||
| 46364216 | 115年第1季綜合損益表 | 2026-05-13 | Chinese | ||
| 46363836 | 115年第1季資產負債表 | 2026-05-13 | Chinese | ||
| 46366990 | 本公司董事會決議辦理限制員工權利新股收回註銷 暨訂定減資基準日事宜 | 2026-05-13 | Chinese | ||
| 46367356 | 公告本公司董事會通過115年第一季合併財務報告 | 2026-05-13 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Hindustan Bio Sciences Ltd.
Develops and distributes biotech-derived products and pharm…
|
532041 | IN | Manufacturing |
|
HINOVA PHARMACEUTICALS INC.
Clinical-stage developer of cancer and metabolic disease sm…
|
688302 | CN | Manufacturing |
|
Hin Sang Group (International) Holding Co. Ltd.
Develops and distributes children's healthcare, TCM, person…
|
6893 | HK | Manufacturing |
|
HISAMITSU PHARMACEUTICAL CO.,INC.
A pharmaceutical firm specializing in external pain relief …
|
4530 | JP | Manufacturing |
|
HK inno.N Corporation
A biohealth company developing pharmaceuticals and consumer…
|
195940 | KR | Manufacturing |
|
HLB Genex, Inc.
Develops and produces customized enzyme and microbiome-base…
|
187420 | KR | Manufacturing |
|
HLB INC.
A biopharmaceutical company developing new global anti-canc…
|
028300 | KR | Manufacturing |
|
HLB Life Science CO.,LTD.
Develops anti-cancer drugs and manufactures in vitro diagno…
|
067630 | KR | Manufacturing |
|
HLB Pep Co., Ltd.
Biopharmaceutical firm specializing in peptide-based drug R…
|
196300 | KR | Manufacturing |
|
HLB PHARMACEUTICAL CO., LTD.
Develops and manufactures pharmaceuticals, quasi-drugs, and…
|
047920 | KR | Manufacturing |
PEC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52565/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52565 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52565 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52565 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52565}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PEC (id: 52565)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.